Reviews/Heart Failure Management/Left ventricular assist device destination therapy improves survival in end-stage heart failure
Lvad · HFM-LVAD-02 · v2
For patients with end-stage heart failure who cannot receive a transplant, one randomised trial [9] directly compared an implanted assist device against the best available drug treatment and found far more people alive at one year with the device (52% versus 25%). A later look at the same trial [12] confirmed the benefit held over longer follow-up. Newer-generation pumps report even higher survival [8][10][11][13][14], but those studies had no drug-treatment group to compare against, so they support the direction without re-testing the head-to-head question. The whole direct comparison therefore rests on a single, older trial using a device that is no longer used. The panel judged the direction well supported but the comparative base thin, which is why it stopped short of the top tier.
A single randomised trial in exactly the specified population reported a 48 percent reduction in death with the assist device and one-year survival of 52% versus 25% for optimal medical management [9], a benefit confirmed on extended product-limit follow-up at 52% versus 28% at one year and 29% versus 13% at two years [12]. Modern continuous-flow and magnetically-levitated devices report substantially higher absolute survival, such as 58% at two years [10], 83% at two years [13], 88% at one year [11], and roughly 60% at four years [14], but none carried a medical-therapy comparator. Registry cohorts [5][7][14] describe only absolute device survival. The direct comparative signal rests on one trial [9][12]. The contested point: The division is whether a single older-device trial [9] plus its own re-analysis [12] can carry a claim about contemporary therapy, given that every modern survival figure [8][10][11][13][14] comes from devices never randomised against optimal medical therapy. The durability of the effect is also contested, since the two-year difference in [9] (23% vs 8%) carried P=0.09.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The direct LVAD-vs-OMT comparison rests on a single randomised trial (REMATCH, [9], N=129) plus its own re-analysis ([12]); these are not independent studies, and no second head-to-head RCT exists in the corpus.
Device-generation indirectness: REMATCH used a first-generation pulsatile device. Every modern DT survival figure ([8][10][11][13][14]) comes from continuous-flow or magnetically-levitated devices, none of which was RCT-tested against OMT, so the claim's application to contemporary therapy is extrapolation.
Where it remains uncertain. The comparative evidence is a single trial using a now-superseded pulsatile device; modern devices [8][10][11][13][14] show high absolute survival but were never randomised against optimal medical therapy.
Aleatory
The sole direct comparison [9] randomised only 129 patients, so the estimated effect carries sampling variability (relative risk 0.52, 95% CI 0.34–0.78).
Epistemic
Only one randomised comparison against optimal medical therapy exists [9][12]; the comparison has not been independently reproduced in this corpus.
Inferential
Carrying the pulsatile-device result [9] onto continuous-flow and magnetically-levitated devices assumes the comparative benefit transfers across device generations, which the corpus does not test.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Direct RCT evidence of a significant survival benefit of LVAD DT over optimal medical management in the exact claim population.
“The rates of survival at one year were 52 percent in the device group and 25 percent in the medical-therapy group (P=0.002), and the rates at two years were 23 percent and 8 percent (P=0.09), respectively.”
Panel auditInternal validity: high · scope of inference: NYHA class IV end-stage heart failure patients ineligible for cardiac transplantation, pulsatile-flow device era.Key limitations: older pulsatile device technology · high adverse-event frequency in device group · small sample
Independent RCT reaffirming the LVAD-vs-medical-therapy survival advantage and extending survival with continuous-flow devices (58% at 2 years).
“Patients with advanced heart failure have improved survival rates and quality of life when treated with implanted pulsatile-flow left ventricular assist devices as compared with medical therapy.”
Panel auditInternal validity: high · scope of inference: Advanced heart failure patients ineligible for transplantation, comparing continuous- versus pulsatile-flow devices.Key limitations: no medical-therapy arm · device-versus-device only · background claim not tested here
Extended follow-up confirming the survival benefit persists over the full trial period.
“The survival rates for patients receiving left ventricular assist devices (n = 68) versus patients receiving optimal medical management (n = 61) were 52% versus 28% at 1 year and 29% versus 13% at 2 years ( P = .008, log-rank test).”
Panel auditInternal validity: high · scope of inference: End-stage heart failure patients from REMATCH ineligible for transplant, pulsatile-flow device era with extended follow-up.Key limitations: older pulsatile device technology · small sample · crossover of some medical-therapy patients
Both arms receive LVAD destination therapy; there is no medical-therapy comparison on which to read the claim.
Panel auditInternal validity: medium · scope of inference: Continuous-flow destination-therapy LVAD recipients, comparing implanting center type.Key limitations: no medical-therapy arm · observational registry · center-type confounding
4 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The claim's direction is carried by a positive, exactly-matched RCT confirmed over time, but the comparative evidence is a single trial using an obsolete device with no modern head-to-head vs OMT, which holds confidence below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No modern-device RCT versus optimal medical therapy. Every contemporary survival figure comes from devices never compared head-to-head with medical therapy [8][10][11][13][14], so the claim's application to current practice is extrapolation from [9]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised trial of a current magnetically-levitated or continuous-flow device against contemporary optimal medical therapy in transplant-ineligible end-stage heart failure, with all-cause survival as the primary endpoint.
Open question: Does a modern magnetically-levitated or continuous-flow assist device improve survival compared with contemporary optimal medical therapy in transplant-ineligible end-stage heart failure? Why it is still open: All modern survival data in the corpus [8][10][11][13][14] lack a medical-therapy comparator; the only direct comparison [9] used a superseded pulsatile device.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19